InvestorsHub Logo
Followers 1055
Posts 189434
Boards Moderated 1
Alias Born 06/19/2009

Re: ANIA77 post# 889

Monday, 07/03/2017 10:46:42 AM

Monday, July 03, 2017 10:46:42 AM

Post# of 3504
Anytime. CBLI 's biodefense treatment, entolimod, is now on the fast track toward a Marketing Authorization Application (MAA). 3.7m float. No debt.

why short interest decreased by 50% recently? Radiation Treatment Marketing Approval Equal BlockBuster. and current cap around 30m. W/ very solid balance sheet and strong cash on hand.

https://seekingalpha.com/amp/news/3257265-cleveland-go-european-marketing-application-radiation-countermeasure-entolimod-shares-ahead

My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.